# Elamipretide (SS-31)

> A synthetic mitochondrial tetrapeptide given FDA accelerated approval in 2025 for Barth syndrome only. No trial has tested it against ageing.

Source page: https://peptioresearch.com/peptides/elamipretide/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-23

## At a glance

- Research status: Approved for a medical indication
- Also known as: SS-31, SS31, MTP-131, Bendavia, Forzinity, RX-31, Ocuvia
- Identifiers: CAS 736992-21-5; PubChem CID 11764719; DrugBank DB11981; ChEMBL CHEMBL3833370; INN elamipretide
- Molecular weight: 639.8

## What the research shows

Each claim is labelled with the strongest kind of study that supports it, which way the evidence points, and how confident that reading is.

### In Barth syndrome, the randomised crossover phase of TAZPOWER (12 patients, 12 weeks per arm) did not meet either primary endpoint, the 6-minute walk test or a Barth syndrome symptom scale.

- Evidence: Human randomised trial. No effect found. Low confidence.
- Sources: [1][2]

TAZPOWER randomised 12 people with Barth syndrome to elamipretide or placebo for 12 weeks, then after a 4-week washout switched them to the opposite arm for another 12 weeks. The primary endpoints were improvement on the 6-minute walk test, the distance a person can walk in six minutes, and on the Barth syndrome Symptom Assessment scale. The authors report that in this randomised part neither primary endpoint was met. FDA's label for Forzinity states that it was not superior to placebo on these primary endpoints and that increases in knee extensor muscle strength were not observed during the randomised trial.

Caveats:
- Twelve participants, the whole randomised evidence base in the approved indication.
- Only the abstract of the trial publication was read.

### In primary mitochondrial myopathy, the phase 3 MMPOWER-3 trial (218 adults, 24 weeks) did not meet its primary endpoints of 6-minute walk distance and fatigue.

- Evidence: Human randomised trial. No effect found. Moderate confidence.
- Sources: [3]

MMPOWER-3 randomised 218 adults with primary mitochondrial myopathy, 109 to elamipretide and 109 to placebo, for 24 weeks. The difference from placebo in 6-minute walk distance was -3.2 m (95% CI -18.7 to 12.3; p = 0.69), and in total fatigue score -0.07 (95% CI -0.10 to 0.26; p = 0.37). Treatment was described as well tolerated, with most adverse events mild to moderate.

Caveats:
- Only the abstract was read.
- A post hoc genotype analysis has been published but was not read for this page, and nothing from it is used.

### In primary mitochondrial myopathy, the MMPOWER-2 crossover trial (30 patients, 4 weeks per arm) did not reach statistical significance on its primary endpoint, 6-minute walk distance: 398.3 m on elamipretide against 378.5 m on placebo.

- Evidence: Human randomised trial. No effect found. Low confidence.
- Sources: [4]

MMPOWER-2 was a randomised, double-blind, placebo-controlled crossover in 30 patients, each receiving elamipretide and placebo for 4 weeks. Patients walked 398.3 m on elamipretide and 378.5 m on placebo, a difference of 19.8 m (95% CI -2.8 to 42.5; P = 0.0833), which does not meet the conventional 0.05 threshold. Injection site reactions occurred in 80% of patients on elamipretide, and no serious adverse events or deaths were reported.

Caveats:
- Thirty patients over 4 weeks per arm.
- The larger and longer MMPOWER-3 trial found no difference.
- Only the abstract was read.

### In a phase 1/2 trial of 36 patients with primary mitochondrial myopathy, treated for 5 days, the highest-dose arm (0.25 mg/kg/h) walked 64.5 m farther at day 5 against 20.4 m with placebo (p = 0.053, not significant); an adjusted model reached p = 0.0297.

- Evidence: Human randomised trial. Mixed. Very low confidence.
- Sources: [5]

MMPOWER-1 gave intravenous elamipretide at several doses or placebo to 36 participants. The primary endpoint was the change in 6-minute walk distance after 5 days. The highest-dose arm walked a mean of 64.5 m farther, against 20.4 m in the placebo group (p = 0.053). In a model adjusted for other covariates the figures were 51.2 m against 3.0 m (p = 0.0297), and the authors report a dose-dependent increase (p = 0.014).

Caveats:
- Five days of treatment, split across several dose arms of 36 people in total. This is an early, exploratory result.
- Only the abstract was read.

### In a phase 3 trial of 102 people with nuclear-DNA primary mitochondrial disease (NuPOWER, 48 weeks), no result has been published or posted; the sponsor has said only that the data support development in the POLG1 subgroup.

- Evidence: Human randomised trial. Insufficient evidence. Very low confidence.
- Sources: [6][7]

The ClinicalTrials.gov record describes a randomised, quadruple-masked trial with 102 participants enrolled, 48 weeks of treatment and a primary endpoint of 6-minute walk distance. It records completion on 4 December 2024 and no posted results, and no publication was found. In a May 2026 press release, Stealth BioTherapeutics, the sponsor, said the NuPOWER results "support development of elamipretide in POLG1 subgroup" and announced a conference poster on a "genotype-dependent response" in that subgroup. The release gives no figures and does not say whether the primary endpoint was met.

Caveats:
- Recorded so the gap is visible. The only account of the outcome is the sponsor's own, without numbers, and a subgroup singled out after a trial is a lead for a new trial, not a result.

### In stable heart failure with reduced ejection fraction, the phase 2 PROGRESS-HF trial (71 patients, 4 weeks) did not change left ventricular end-systolic volume, its primary endpoint.

- Evidence: Human randomised trial. No effect found. Moderate confidence.
- Sources: [8]

PROGRESS-HF randomised 71 patients with heart failure with reduced ejection fraction to 4 mg or 40 mg of elamipretide or placebo, once daily for 28 days. The primary endpoint was the change in left ventricular end-systolic volume, a heart-size measure, from baseline to week 4. The differences from placebo were -0.3 mL (95% CI -4.6 to 4.0; P = 0.90) for the 4 mg arm and 2.3 mL (95% CI -1.9 to 6.5; P = 0.28) for the 40 mg arm. Rates of drug-related adverse events were similar across the three groups.

Caveats:
- Four weeks, 71 patients, and a surrogate endpoint rather than symptoms, hospitalisation or survival.
- Only the abstract was read.

### In a single-infusion trial in heart failure with reduced ejection fraction, the highest-dose cohort (0.25 mg/kg/h, 8 patients) had left ventricular end-diastolic volume 18 mL lower than placebo at the end of the infusion.

- Evidence: Human randomised trial. Supportive. Very low confidence.
- Sources: [9]

This double-blind, placebo-controlled, ascending-dose trial enrolled three cohorts of 8 patients on elamipretide and a placebo group of 12. At the highest dose, left ventricular end-diastolic volume fell by 18 mL (P = 0.009) at the end of a single infusion. No serious adverse events were reported.

Caveats:
- One infusion, measured at its end. A heart-volume measure is a surrogate, not a clinical outcome.
- The abstract names no primary endpoint.
- The 4-week PROGRESS-HF trial in the same condition found no effect on a related volume measure.
- Only the abstract was read.

### In patients having treatment for a heart attack (STEMI), the phase 2a EMBRACE STEMI trial did not reduce infarct size, its primary endpoint.

- Evidence: Human randomised trial. No effect found. Moderate confidence.
- Sources: [10][11]

EMBRACE STEMI, listed on ClinicalTrials.gov with 300 participants enrolled, measured infarct size as the area under the curve of the cardiac enzyme CK-MB over 72 hours. It was 5785 plus or minus 426 ng h/mL with placebo and 5570 plus or minus 486 ng h/mL with the drug, then called MTP-131, a difference the authors report as not significant. Secondary MRI measures were also null.

Caveats:
- Enzyme-based infarct size is a surrogate, not a measure of later heart failure or death.
- Only the abstract was read.

### In dry age-related macular degeneration with geographic atrophy, the phase 2 ReCLAIM-2 trial (176 patients, 48 weeks) did not meet its primary endpoints.

- Evidence: Human randomised trial. No effect found. Moderate confidence.
- Sources: [12]

ReCLAIM-2 randomised 176 patients, 117 to elamipretide and 59 to placebo, for 48 weeks. The primary endpoints were change in low-luminance best-corrected visual acuity and change in the area of geographic atrophy, and neither reached statistical significance. An exploratory measure of the ellipsoid zone, a layer of the retina, progressed 43% less on average (nominal P = 0.0034). Adverse events were reported in 86% of those on elamipretide and 71% on placebo.

Caveats:
- The ellipsoid-zone result is exploratory and a surrogate, not a vision outcome.
- A phase 3 trial, ReNEW, has enrolled 313 people and has an estimated primary completion of August 2027. No results yet.
- Only the abstract was read.

### In Leber hereditary optic neuropathy, a phase 2 trial of elamipretide eye drops in 12 patients over 52 weeks did not improve best-corrected visual acuity, its primary endpoint.

- Evidence: Human randomised trial. No effect found. Low confidence.
- Sources: [13]

Twelve patients with Leber hereditary optic neuropathy, an inherited cause of vision loss, were treated over a 52-week double-masked period. Best-corrected visual acuity in treated eyes was not significantly different from vehicle-treated eyes at any time point. No serious adverse events were reported.

Caveats:
- Twelve patients.
- Only the abstract was read.

### In 39 older adults aged 60 to 85, enrolled because their muscle mitochondria were poorly functioning, a single infusion of elamipretide produced a borderline rise in a muscle energy surrogate (ATPmax) immediately afterwards and had no effect on fatigue resistance.

- Evidence: Human randomised trial. Mixed. Very low confidence.
- Sources: [14][15]

This randomised, double-blind, placebo-controlled trial measured ATPmax, the maximal rate at which muscle makes ATP, by in vivo spectroscopy. Immediately after one infusion, the absolute change was P = 0.055 and the percentage change P = 0.045 against placebo; by day 7 there was no difference. There was no significant effect on fatigue resistance. It is the only published randomised trial in older adults.

Caveats:
- ATPmax is a surrogate. The trial did not measure ageing, frailty, function over time or lifespan.
- One dose, with the effect gone a week later.
- The paper calls participants "healthy older adult subjects" who were "enrolled based on the presence of poorly functioning mitochondria"; the trial registry marks them as not healthy volunteers and lists 41 enrolled.
- Only the abstract was read.

### In an open-label extension of TAZPOWER with no comparator group, 6-minute walk distance in Barth syndrome was higher than at baseline, by 95.9 m at 36 weeks and by a cumulative 96.1 m at week 168, each in the 8 patients who reached that point.

- Evidence: Human case report. Supportive. Very low confidence.
- Sources: [1][16][2]

Ten patients from the randomised phase continued on open-label elamipretide; 8 reached week 168. The extension's primary endpoints were safety and tolerability. Walk distance improved by 95.9 m at 36 weeks (p = 0.024) and by a cumulative 96.1 m at week 168 (P = .003), each measured against the patients' own baseline, not against placebo. FDA's label describes the extension as single-arm, and it is the source of the strength data on which the accelerated approval rests.

Caveats:
- No control group. Everyone knew they were receiving the drug, so improvement over time cannot be separated from practice, natural history or expectation.
- The same patients showed no walk-test benefit in the randomised phase.
- Ten patients entered and 8 remained at week 168.
- Only the abstracts of the publications were read.

### In C57BL/6J mice, 8 weeks of elamipretide was reported to slow frailty accumulation, without detectable changes in tissue epigenetic or transcriptomic age. Lifespan was not measured.

- Evidence: Animal research. Mixed. Low confidence.
- Sources: [17]

The study measured a frailty index, cardiac strain, muscle force and fatigue. The authors report that elamipretide mitigated frailty accumulation, and that they did not detect statistically significant changes in gene expression in most groups. The paper's title states the effect came without detectable changes in tissue epigenetic or transcriptomic age.

Caveats:
- Mouse study over 8 weeks. The frailty index and tissue measures are surrogates.
- The age of the mice at treatment is not given in the abstract.
- Only the abstract was read.

### In aged female mice, 8 months of intermittent elamipretide was reported to preserve exercise tolerance and left ventricular mass, but did not reproduce the kidney benefit earlier reported with continuous treatment. Lifespan was not measured.

- Evidence: Animal research. Supportive. Low confidence.
- Sources: [18]

Aged female mice received intermittent elamipretide for 8 months. The authors report preserved exercise tolerance and left ventricular mass, and that intermittent treatment "did not affect kidney function as previously reported using continuous treatment".

Caveats:
- Mouse study. The strain is not given in the abstract.
- Exercise tolerance and heart mass are functional and structural measures, not lifespan.
- Only the abstract was read.

### In old C57BL mice, 8 weeks of SS-31 improved diastolic heart function, but did not improve cardiac function in old mice engineered to express mitochondrial catalase (mCAT). Lifespan was not measured.

- Evidence: Animal research. Mixed. Low confidence.
- Sources: [19]

Old mice treated for 8 weeks showed improved diastolic function, the heart's ability to relax and fill. In old mCAT mice the authors report no improvement in cardiac function.

Caveats:
- Mouse study over 8 weeks with heart-function surrogates.
- The strain is taken from the indexing terms (C57BL), not the abstract text.
- Only the abstract was read.

## Reported and theoretical risks

### Injection site reactions

- Evidence: Human randomised trial. Severity: mild.
- Sources: [2][4][16]

FDA's label lists injection site reactions as the most common adverse reactions. In the MMPOWER-2 crossover trial they occurred in 80% of patients while on elamipretide, and the TAZPOWER extension reports them as the most common adverse events.

### Hypersensitivity reactions, including serious allergic reactions

- Evidence: Mechanistic reasoning. Severity: serious.
- Sources: [2]

The label warns of hypersensitivity reactions, including serious allergic reactions requiring emergency medical intervention. They have included rash, papular lesions and eczematous dermatitis, and may occur within minutes to months after treatment starts. Serious hypersensitivity to elamipretide or any excipient is a contraindication.

### Raised eosinophil counts

- Evidence: Mechanistic reasoning. Severity: unknown.
- Sources: [2]

The label states that increases in absolute eosinophil counts, a type of white blood cell, were noted frequently in studies and generally peaked around 90 days after first exposure. It reports them as not associated with clinical manifestations.

### Not approved for neonates because of benzyl alcohol

- Evidence: Mechanistic reasoning. Severity: serious.
- Sources: [2]

The approved product contains benzyl alcohol, and the label states that Forzinity is not approved for use in neonates.

### Long-term safety and cancer risk not established

- Evidence: Human case report. Severity: unknown.
- Sources: [2][16]

The label states that carcinogenicity studies have not been conducted, and that clinical studies did not enrol people with Barth syndrome aged 65 or older. The longest follow-up published is the TAZPOWER extension, in which 8 patients reached week 168.

## Regulatory status

- US, FDA: approved limited indication (as of 2025-09-19). FDA granted accelerated approval to Forzinity (elamipretide) injection on 19 September 2025 as a new molecular entity, under priority review, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. The approval is based on knee extensor muscle strength, which the label calls an intermediate clinical endpoint, and continued approval may be contingent on verification of clinical benefit in a post-approval randomised, double-blind, placebo-controlled trial. Read from Drugs@FDA, FDA's press release and the label. [20]
- EU, EMA: not approved (as of 2022-05-16). EMA lists an orphan designation for elamipretide in myopathic mitochondrial DNA depletion syndrome, granted on 16 May 2022. EMA states that orphan designation does not mean the medicine is available or authorised for use. Only this one designation was confirmed; EMA's search page could not be retrieved, so other designations, if any, were not checked. [21]

## Context

Elamipretide is approved in the United States for one narrow use. On 19 September 2025, FDA granted accelerated approval to Forzinity, an elamipretide injection, to improve muscle strength in people with Barth syndrome, a rare inherited mitochondrial disease, who weigh at least 30 kg ([source](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215244), [source](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome)). The approval rests on knee extensor strength, which the label calls an intermediate clinical endpoint, and those strength gains come from an uncontrolled extension in 10 patients. The label itself states that Forzinity "was not superior to placebo" on the randomised trial's primary endpoints and that strength increases "were not observed during the randomized trial" ([source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75)). It came after a first attempt failed: in May 2025 the company said FDA had issued a complete response letter, a refusal to approve in that review cycle, and that FDA had then agreed to consider knee extensor strength as an intermediate endpoint for accelerated approval if the application was resubmitted ([source](https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-path-forward-despite-disappointing-delay-for-ultra-rare-barth-syndrome-302467718.html)). The label says continued approval may depend on a confirmatory trial. A randomised phase 4 trial in Barth syndrome, 4TAZPower, began recruiting in July 2026 ([source](https://clinicaltrials.gov/study/NCT07531251)). No trial has tested elamipretide against ageing, lifespan or any ageing outcome.

## What it is

Elamipretide is a synthetic tetrapeptide, a chain of four amino acids, better known in laboratory papers and online as SS-31; earlier trials called it MTP-131 or Bendavia. FDA's label describes it as a mitochondrial cardiolipin binder that localises to the inner mitochondrial membrane ([source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75)). That is a description of where it acts, not evidence that it does anything useful there.

The label gives the structure as D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2. Two of those residues, a D-form arginine and a modified tyrosine, cannot be written in the standard one-letter amino acid code, so no sequence is shown on this page. The molecular weight given, 639.8, is for the free base listed by PubChem ([source](https://pubchem.ncbi.nlm.nih.gov/compound/11764719)); the label's figure of 749.2 is for the trihydrochloride salt in the approved product.

## Where the evidence stands

Elamipretide has been through randomised trials in several diseases, and most of the published ones missed their primary endpoints.

> **Key point.**
> In Barth syndrome, the randomised phase of TAZPOWER (12 patients) met neither primary endpoint ([source](https://pubmed.ncbi.nlm.nih.gov/33077895/)). In mitochondrial myopathy, MMPOWER-3 (218 patients, 24 weeks) found no difference in walk distance or fatigue ([source](https://pubmed.ncbi.nlm.nih.gov/37268435/)). Trials in heart failure ([source](https://pubmed.ncbi.nlm.nih.gov/32068002/)), heart attack ([source](https://pubmed.ncbi.nlm.nih.gov/26586786/)), dry macular degeneration ([source](https://pubmed.ncbi.nlm.nih.gov/39605874/)) and an inherited optic neuropathy ([source](https://pubmed.ncbi.nlm.nih.gov/37923251/)) also missed their primary endpoints.

The positive human results are smaller, shorter or uncontrolled: a 5-day phase 1/2 trial ([source](https://pubmed.ncbi.nlm.nih.gov/29500292/)), a single infusion in heart failure ([source](https://pubmed.ncbi.nlm.nih.gov/29217757/)), and the open-label TAZPOWER extension ([source](https://pubmed.ncbi.nlm.nih.gov/38602181/)). NuPOWER, a 102-person phase 3 trial in nuclear-DNA mitochondrial disease, is recorded as completed in December 2024 with no results posted or published ([source](https://clinicaltrials.gov/study/NCT05162768)). Its sponsor has since said, in a May 2026 press release without figures, that the data "support development of elamipretide in POLG1 subgroup", meaning people with POLG1 mutations ([source](https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-updates-on-elamipretide-in-barth-syndrome-and-polg-disease-at-euromit-2026-302779660.html)).

## Ageing: what has and has not been studied

The one published randomised trial in older adults gave 39 people aged 60 to 85, enrolled because their muscle mitochondria were poorly functioning, a single infusion and measured ATPmax, a spectroscopy measure of how fast muscle can make ATP ([source](https://pubmed.ncbi.nlm.nih.gov/34264994/)). It rose borderline immediately afterwards, was gone by day 7, and fatigue resistance did not change. A 30-person open-label safety study in adults aged 65 to 80 is registered, with no results ([source](https://clinicaltrials.gov/study/NCT07275424)).

> **Evidence.**
> The ageing claims made for SS-31 rest on mice. Studies in old mice lasted 8 weeks to 8 months and measured frailty scores, heart function, muscle force and exercise tolerance ([source](https://pubmed.ncbi.nlm.nih.gov/40080911/), [source](https://pubmed.ncbi.nlm.nih.gov/36840897/), [source](https://pubmed.ncbi.nlm.nih.gov/32648542/)). None measured lifespan, and the research packet behind this page found no lifespan study of elamipretide in any species. The most recent study's title reports its effect came "without detectable changes" in tissue epigenetic or transcriptomic age ([source](https://pubmed.ncbi.nlm.nih.gov/40080911/)).

## The approval covers one product

FDA's approval covers Forzinity, the approved product, for its labelled indication in Barth syndrome. It says nothing about the identity, purity or safety of material sold under the same name, and no published analysis of such products was found.

> **Caution.**
> The label warns of hypersensitivity reactions, including serious allergic reactions requiring emergency medical treatment, which may appear within minutes to months of starting ([source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75)).

## Sources

1. Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. 2021. https://doi.org/10.1038/s41436-020-01006-8
2. FORZINITY (elamipretide) injection, prescribing information (Revised 9/2025). DailyMed, U.S. National Library of Medicine (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75
3. Karaa A et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023. https://doi.org/10.1212/WNL.0000000000207402
4. Karaa A, Haas R, Goldstein A. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2020. https://doi.org/10.1002/jcsm.12559
5. Karaa A, Haas R, Goldstein A. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018. https://doi.org/10.1212/WNL.0000000000005255
6. A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower. ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT05162768
7. Stealth BioTherapeutics to Present Updates on Elamipretide in Barth Syndrome and POLG Disease at Euromit 2026. Stealth BioTherapeutics (press release, PR Newswire). 2026. https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-updates-on-elamipretide-in-barth-syndrome-and-polg-disease-at-euromit-2026-302779660.html
8. Butler J et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure. 2020. https://doi.org/10.1016/j.cardfail.2020.02.001
9. Daubert MA, Yow E, Dunn G. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure. 2017. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004389
10. Gibson CM et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal. 2016. https://pubmed.ncbi.nlm.nih.gov/26586786/
11. Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events. ClinicalTrials.gov. 2014. https://clinicaltrials.gov/study/NCT01572909
12. Ehlers JP et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmology Science. 2025. https://pubmed.ncbi.nlm.nih.gov/39605874/
13. Karanjia R, Sadun AA. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology. 2024. https://doi.org/10.1016/j.ophtha.2023.10.033
14. Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. https://doi.org/10.1371/journal.pone.0253849
15. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of a Single Intravenous Dose of MTP-131 (Bendavia™) on Skeletal Muscle Function in the Elderly. ClinicalTrials.gov. 2020. https://clinicaltrials.gov/study/NCT02245620
16. Thompson WR et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. 2024. https://doi.org/10.1016/j.gim.2024.101138
17. Mitchell W et al. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. 2025. https://pubmed.ncbi.nlm.nih.gov/40080911/
18. Campbell MD, Samuelson AT, Chiao YA. Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. GeroScience. 2023. https://pubmed.ncbi.nlm.nih.gov/36840897/
19. Chiao YA, Zhang H, Sweetwyne M. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020. https://pubmed.ncbi.nlm.nih.gov/32648542/
20. Drugs@FDA: FORZINITY (elamipretide hydrochloride), NDA 215244. U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215244
21. EU/3/22/2614: orphan designation for treatment of myopathic mitochondrial DNA depletion syndrome (elamipretide). European Medicines Agency. 2022. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2614
